Sensei Biotherapeutics (NASDAQ:FTH) Stock Price Down 7.8% – Time to Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price traded down 7.8% during mid-day trading on Wednesday. The stock traded as low as $25.10 and last traded at $24.7830. 194,579 shares were traded during trading, a decline of 19% from the average session volume of 239,758 shares. The stock had previously closed at $26.89.

Analyst Ratings Changes

Several analysts have commented on the stock. Robert W. Baird started coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They issued an “outperform” rating and a $57.00 price objective on the stock. Needham & Company LLC initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, August 21st. They set a “buy” rating and a $56.00 target price for the company. TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a report on Wednesday, September 9th. They issued a “buy” rating on the stock. JonesTrading started coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They set a “buy” rating and a $55.00 price objective for the company. Finally, Guggenheim started coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $56.25.

Sensei Biotherapeutics Price Performance

The company’s 50 day simple moving average is $32.00. The stock has a market cap of $635.66 million, a PE ratio of -0.17 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($5.04) by $2.20. On average, research analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently modified their holdings of the business. Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at about $22,758,000. Alyeska Investment Group L.P. purchased a new position in Sensei Biotherapeutics during the second quarter worth approximately $3,610,000. Stempoint Capital LP acquired a new stake in Sensei Biotherapeutics in the first quarter valued at approximately $4,188,000. Bank of America Corp DE grew its holdings in Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares in the last quarter. 10.50% of the stock is currently owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.